Molecular medicine today

Subject Index

Author Index

Books Reviewed

1995

Vol 1
Issues 1–9

ISSN 1357 4329

Molecular Medicine Today

Elsevier Trends Journals
68 Hills Road
Cambridge
UK CB2 1LA
Tel: +44 1223 315961
Fax: +44 1223 464430
+44 1223 321410
e-mail: mmt.trends@elsevier.co.uk

Advisory Editorial Board S. Agrawal, Worcester, USA
P. Berg, Stanford, USA
H. Blau, Stanford, USA
T. Blundell, London, UK
D. Choi, St Louis, USA
T. Cox, Cambridge, UK
K. Culver, Gaithersburg, USA
K. Davies, Oxford, UK
R. Flavell, New Haven, USA
D. Gordon, London, UK
M. Noble, Salt Lake City, USA
W. Petri, Charlottesville, USA
B. Ponder, Cambridge, UK
D. Prockop, Philadelphia, USA
L-C. Tsui, Toronto, Canada
H. zur Hausen, Heidelberg, Germany

Editor Rebecca Jones

Assistant Editors Catherine Brooksbank and Fiona Watson

News Editor Caroline Ash

Editorial Administrator Sandra Taylor

Managing Editor Theresa Saklatvala

Publisher Peter Desmond

© 1996 Elsevier Science Ltd. All rights reserved.

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science Ltd. Except as outlined in the terms and conditions, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA.

AUTHOR INDEX

Abbreviations: (B), The books; (C), The letters; (L), The literature; (M), The meetings; (N), News; (P), Perspectives; (W), The web

A

Aarden, L.A., see van der Pouw Kraan, T.C.T.M.
Alayash, A.I. and Cashon, R.E., Haemoglobin and free radicals: implications for the development of a safe blood substitute 122
Altman, D., see Steinman, L.
Altman, J., An Alzheimer's mouse at last? (N) 1
Altman, J., Another clue in the Alzheimer's puzzle (N) 210
Altman, J., Developing therapies for Alzheimer's disease (P) 404
Altman, J., Mutant SOD may be the killer in motor neurone disease (N) 157
Altman, J., Neurological disorders: stem cells for damaged brains? (N) 350
Altman, J., Neurotrophic factors head for the clinic (N) 159
Altman, J., No animal link to Creutzfeldt–Jakob disease (N) 393
Andrews, P.A., Zhou, W. and Sacks, S.H., Tissue synthesis of complement as an immune regulator 202
Ash, C., Alternative to bone marrow transplantation (N) 107
Ash, C., Genome wizard (N) 210
Ash, C., Hib vaccine (N) 51

B

Bach, J-F., Tolerance induction in transplantation and autoimmune diseases (M) 302
Bagshawe, K.D., Antibody-directed enzyme prodrug therapy for cancer: its theoretical basis and application 424
Baker, D.A. and Carucci, D.J., Malaria transmission on the web (W) 356
Barker, D.J.P., Intrauterine programming of adult disease 418
Barnes, P.J., Air pollution and asthma: molecular mechanisms 149
Barrett, J., Delivery devices and protecting the next generation from nicotine (N) 351
Beserman, P., see Schwartz, M.
Bevan, S., A mix of genes and radiation for tumour necrosis (L) 304
Bevan, S., The unwanted complement (L) 163
Blackwell, C.C., Weir, D.M. and Busuttil, A., Infectious agents, the inflammatory responses of infants and sudden infant death syndrome (SIDS) 72
Bode, A.P., see Read, M.S.
Bouchard, C., The genetics of obesity: from genetic epidemiology to molecular markers 45
Bradley, D., Halting cellular waste disposal could halt disease (N) 256
Brines, R., Turn on, tune in, log out (W) 10
Brooksbank, R.A., A second step on the pathway to SCID (L) 353
Brown, P., Ebola origin remains a mystery (N) 157
Browne, M.J., Gloger, I.S., Hodgson, J.E. and Robinson, J.H., The importance of genome analysis to the drug discovery process 373
Busuttil, A., see Blackwell, C.C.

C

Carrell, R., Skinner, R., Wardell, M. and Whisstock, J., Antithrombin and heparin 226
Carucci, D.J., see Baker, D.A. 356
Cashon, R.E., see Alayash, A.I.
Chisholm, J.C., see Davis, J.N.
Collins, M. and Porter, C., Gene therapy (M) 396
Cook, G.C., Infectious diseases (B) 262

D

Davis, J.N., Hunnicutt, Jr, E.J. and Chisholm, J.C., A mitochondrial bottleneck hypothesis of Alzheimer's disease 240
Deugnier, M-A., see Glukhova, M.
Dickinson, P., Dorin, J.R. and Porteous, D.J., Modelling cystic fibrosis in the mouse 140
Diehl, V., see Küppers, R.
Digoutte, J-P., Infectious diseases in the year of Louis Pasteur (M) 160
Dixon, B., Horror bacteria (N) 105
Domb, A.J., Polymeric carriers for regional drug therapy 134
Domingo, E., see Novella, I.S.
Dorin, J.R., see Dickinson, P.

E

Eichler, J. and Houghten, R.A., Generation and utilization of synthetic combinatorial libraries 174
Evans, K.L., X-chromosomal linkage of bipolar affective disorder (L) 403

F

Fisher, L.J. and Gage, F.H., Novel therapeutic directions for Parkinson's disease 181
FRAME, Defending the use of animals to research human disease (C) 308
Fricker, J., Baboons, stem cells, facilitator cells and AIDS (N) 349
Fricker, J., Sandoz prizes (N) 255

G

Gage, F.H., see Fisher, L.J.
Gardner, E., More research grants (N) 211
Gardner, E., Research grants (N) 106
Geary, J., Plumbing the depths of crocodile blood (N) 1
Glaser, V., Neurological disorders: consensus on future directions in Parkinson's disease research (N) 350
Gloger, I.S., see Browne, M.J.
Glukhova, M., Deugnier, M-A. and Thiery, J.P., Tumour progression: the role of cadherins and integrins 84
Gottlieb, M., Molecular approaches to parasitic disease control (N) 159
Greaves, D.R., A tale of two polyps (L) 214
Greaves, D.R., CD34 gene regulation – an entry point to stem cell biology (L) 5
Greaves, D.R., CMV PCR for BMT (L) 402
Greaves, D.R., Meanwhile, back at the mucosa... (L) 260
Greaves, D.R., MIP-1α: a chemokine at the heart of inflammation (L) 352

Greaves, D.R., Muscling in on gene therapy (L) 162
Greaves, D.R., Rescue of apoE knockout mice by haematopoietic cells (L) 56
Greaves, D.R., The long, the short and the *TAL-1* gene (L) 352
Greaves, D.R., Transgenic expression goes to the (vessel) wall (L) 110
Greenstein, A.J., see Greenstein, R.J.
Greenstein, R.J. and Greenstein, A.J., Is there clinical, epidemiological and molecular evidence for two forms of Crohn's disease? 343
Günzburg, W.H. and Salmons, B., Virus vector design in gene therapy 410

H

Hansmann, M-L., see Küppers, R.
Hanson, L.Å., see Lomonte, B.
Harby, K., Fetal surgery: the challenge of operating before birth (P) 310
Harby, K., HIV home tests (N) 158
Harper, R., The enlightening role of NO in septic shock (L) 110
Heidenreich, O., Kang, S-H., Xu, X. and Nerenberg, M., Application of antisense technology to therapaeutics 128
Hewitt, C.R.A., Autoreactive T cell receptors not excluded (L) 403
Hickling, J., Munro, A. and Stancliffe, T., Research, development, industry and society (B) 306
Hirschberg, D.L., see Schwartz, M.
Ho, M.M., see Vinson, G.P.
Hodgson, C.P., Gene therapy (M) 396
Hodgson, J.E., see Browne, M.J.
Hoheisel, J.D., Genome analysis (M) 258
Holland, J.J., see Novella, I.S.
Holt, P.G., Environmental antigens and atopic disease: underlying mechanisms and prospects for therapy and prophylaxis 292
Holzman, D.C., NIH grant for *Candida* and AIDS research (N) 300
Hoosen, A.A., Infectious diseases in the year of Louis Pasteur (M) 160
Houghten, R.A., see Eichler, J.
Hunnicutt, Jr, E.J., see Davis, J.N.
Hunter, W.N., Rational drug design: a multidisciplinary approach (plus poster) 31

J

Jack, D.B., Advances in tissue repair (N) 351
Jack, D.B., An exciting new approach to inflammation (N) 158
Jack, D.B., Gloomy outlook for UK biotech research 209
Jack, D.B., Keep taking the tomatoes – the exciting world of nutraceuticals (P) 118
Jack, D.B., New foreign members of the Royal Society (N) 2
Jack, D.B., New functional polymorphism in psoriasis (N) 257
Jack, D.B., Poison gas horror on the Tokyo underground (N) 52
Jack, D.B., Senate FDA reform bill – good news for the pharmaceutical industry? (N) 300
Jack, D.B., Superman paralysed (N) 158
Jack, D.B., Time is running out for Wellcome (N) 3
Jain, R.K., see Saltzman, W.M.
Janda, K.D., Drug discovery and delivery (M) 4
Jochmus, I., Viral evasion of immune surveillance (L) 214
Johnson, M.S., Cornering and catching the common protein fold 188
Jones, R. and Welsh, S., Organizing biomedical resources on the Web (W) 301
Jordan, P.M., see Wood, S.

K

Kaltenbach, E.A. and McCain, L., Ethical, legal and social implications of genome research (W) 400
Kang, S-H., see Heidenreich, O.
Kaye, P., see Kelly, J.
Kelly, J. and Kaye, P., Genetic complementation, LPG2 and *Leishmania* (L) 402
Kingman, S., HIV replication (N) 2
Kingman, S., New type of tuberculosis vaccine (N) 53
Küppers, R., Hansmann, M-L., Diehl, V. and Rajewsky, K., Molecular single-cell analysis of Hodgkin and Reed–Sternberg cells 26

L

Lambert, R., see Wood, S.
Lemoine, N.R., Oncogenes and cancer markers (B) 164
Lichtman, S.N., Role of endogenous enteric organisms in the reactivation of arthritis 385
Liew, F.Y., see Norman, J.E.
Lomonte, B., Tarkowski, A. and Hanson, L.Å., Phospholipase A_2 and inflammation (C) 9
Lusis, A.J., see Shih, D.M.

M

Mahendra, P., Haematology and oncology (B) 216
Mahendra, P., Treatment and prevention of acute GvHD after allogeneic bone marrow transplantation (L) 353
Mahendra, P., Use of $CD34^+$ cells expanded *in vitro* for haemopoietic recovery after high-dose chemotherapy (L) 304
Man, S., Stimulation to a T (L) 352
Man, S., Why men and women are incompatible (N) 394
Martin, R., β_1-Integrin-bright stem cells in human skin (L) 5
Martin, R., Do-it-yourself manuals (B) 112
Martin, R., Giving away the family secrets (N) 394
Maurice, J., Gene vaccines (P) 64
Mayumi, M., see Miyakawa, Y.
McCain, L., see Kaltenbach, E.A.
McLean, A., Breakdown in herd immunity (N) 52
Memo, M., Vezzoni, P. and Spano, P.F., New Frontiers in Molecular Oncology (M) 212
Meyer, K.B., Monoclonal antibodies come of age (B) 58
Miyakawa, Y., Okamoto, H. and Mayumi, M., Classifying hepatitis C virus genotypes 20
Mobley, W.C., see Yuen, E.C.
Morrison, K.E., Mechanisms in motor neurone disease: clues from genetic studies 195
Morrison, K.E., Neurological disease (B) 354
Munro, A., see Hickling, J.

N

Nerenberg, M., see Heidenreich, O.
Norman, J.E. and Liew, F.Y., Nitric oxide (M) 358
Novella, I.S., Domingo, E. and Holland, J.J., Rapid viral quasispecies evolution: implications for vaccine and drug strategies 248

O

O'Brien, C., New UK Chief Scientific Advisor (N) 209
O'Brien, C., Regulation for medical genetics (N) 256
Okamoto, H., see Miyakawa, Y.
Overbaugh, J., HIV: molecular mechanisms (M) 54

P

Pavlakis, G.N., HIV: molecular mechanisms (M) 54
Porteous, D.J., see Dickinson, P.
Porter, C., see Collins, M.
Puddefoot, J.R., see Vinson, G.P.

R

Rajewsky, K., see Küppers, R.
Ramakrishnan, G., A bacterial genetic approach to looking at HIV reverse transcriptase activity (L) 56
Ramakrishnan, G., Lactoferrin: a secreted transcriptional activator (L) 57
Rashbass, J., Accessing GenBank (W) 117

Rashbass, J., Samples from the Superhighway: All in one internet search, Nephrology on the Web, Biotech information, The American Association of Immunology (W) 264
Rashbass, J., Samples from the Superhighway: Harvard Brain Atlas, Spiders, Human genome database, Biosciences Library (W) 114
Rashbass, J., Samples from the Superhighway: Macromolecular images, The National Cancer Institute, Neurosciences on the Internet, Medical multimedia (W) 218
Rashbass, J., Samples from the Superhighway: World Wide Web Worm, The Department of Energy, The Sanger Centre, The World Health Organization (W) 166
Rashbass, J., The Web goes MOO (W) 116
RDS, Defending the use of animals to research human disease (C) 308
Read, M.S. and Bode, A.P., Platelet storage: efforts to extend the shelf-life of platelet concentrates 322
Reardon, W. and Winter, R.M., The molecular pathology of syndromic craniosynostosis 432
Reed, M.J., The discriminant-function test: a marker of Th1/Th2 cell cytokine secretion and breast tumour oestrogen synthesis 98
Roberts, S., see Urban, J.P.G.
Robinson, J.H., see Browne, M.J.
Rollin, B.E., Defending the use of animals to research human disease (C) 308
Rowe, P.M., Genetic testing and society (N) 51
Rowe, P.M., How do antidepressants work? (N) 395
Rowe, P.M., Magnetic resonance elastography: a new dimension for MRI (N) 395
Rowe, P.M., Much progress on the protein-folding problem (N) 257
Rowe, P.M., Neural networks: a bridge between neuroscience and psychology (P) 168
Rowe, P.M., Patenting genes: J. Craig Venter and the Human Genome Project (P) 12

S

Sacks, S.H., see Andrews, P.A.
Šali, A., Comparative protein modeling by satisfaction of spatial restraints 270
Salmons, B., see Günzburg, W.H.
Saltzman, W.M. and Jain, R.K., Drug discovery and delivery (M) 4
Scherer, S.W., ATM – A multi-talented gene (L) 260
Scherer, S.W., Cloning the changes in tumor DNA: RDA continues to fulfil its promises (L) 56
Scherer, S.W., Fibroblast growth factor is sufficient to induce the formation of complete limbs (L) 111
Scherer, S.W., *FRA11B* – Anticipating a chromosomal break (L) 305
Scherer, S.W., Genetic engineering at the chromosomal level (L) 162
Scherer, S.W., Genome analysis (M) 258
Scherer, S.W., Will the real SMA gene please stand up! (L) 5
Scherer, S.W., 'X' marks the spot of the human 'werewolf' gene (L) 215
Schofield, J.P., Metabolic and molecular basis of inherited disease: paper versus electronic media (B) 399
Schwartz, M., Hirschberg, D.L. and Beserman, P., Central nervous system regeneration and the immune system (C) 60
Selden, R.F., see Treco, D.A.
Senior, K., Defending the use of animals to research human disease (P) 220
Senior, K., Homeopathy: science or scam? (P) 266
Senior, K., Monitoring germline gene therapy (N) 105
Shanley, T.P., Warner, R.L. and Ward, P.A., The role of cytokines and adhesion molecules in the development of inflammatory injury 40
Shay, J.W., Aging and cancer: are telomeres and telomerase the connection? 378
Shih, D.M., Welch, C. and Lusis, A.J., New insights into atherosclerosis from studies with mouse models 364
SIMR, Defending the use of animals to research human disease (C) 308
Skinner, R., see Carrell, R.
Snider, B.J., Three genes for Alzheimer's disease (L) 261
Snider, B.J., Three translated triplet repeats (L) 163
Snider, B.J., Transgenic mouse is a knockout model of Neimann-Pick disease (L) 215
Soutar, A.K., Familial hypercholesterolaemia: mutations in the gene for the low-density-lipoprotein receptor 90
Spano, P.F., see Memo, M.
Springer, M.L., Cell implantation treatment for MPS VII (L) 111
Springer, M.L., Gene therapy for restenosis: retinoblastoma to the rescue (L) 57
Stagg, A.J., Migratory dendritic cell precursors – mediators of allograft acceptance? (L) 305
Stancliffe, T., see Hickling, J.
Steinman, L., Waisman, A. and Altmann, D., Major T-cell responses in multiple sclerosis 79
Sterne, G., The regenerating Schwann cell and the axon – who follows who? (L) 6
Stewart, A., First trimester screening for Down's (N) 398
Stewart, A., Getting over the blood–brain barrier (N) 52
Stewart, A., Is thalidomide a mutagen? (N) 210
Stewart, A., New diabetes-associated mutation (N) 2
Stewart, A., Publicly available map of human genes (N) 53
Symons, J.A., Keeping up with cytokines (B) 7

T

Tarkowski, A., see Lomonte, B.
Tebbutt, S.J., Animal studies of cystic fibrosis 336
Thali, M., Cyclosporins: immunosuppressive drugs with anti-HIV-1 activity 287
Thiery, J.P., see Glukhova, M.
Treco, D.A. and Selden, R.F., Non-viral gene therapy 314
Turney, J., Public understanding of medical discovery (P) 359

U

UFAW, Defending the use of animals to research human disease (C) 308
Urban, J.P.G. and Roberts, S., Development and degeneration of the intervertebral discs 329

V

van der Pouw Kraan, T.C.T.M., van Lier, R.A.W. and Aarden, L.A., PGE2 and the immune response (C) 61
van Lier, R.A.W., see van der Pouw Kraan, T.C.T.M.
Veggeberg, S., Unexplained illnesses not unique to Gulf War veterans (N) 299
Vezzoni, P., see Memo, M.
Vines, G., The social causes of ill health (N) 3
Vinson, G.P., Ho, M.M. and Puddefoot, J.R., The distribution of angiotensin II type 1 receptors, and the tissue renin-angiotensin systems 35

W

Waisman, A., see Steinman, L.
Ward, P.A., see Shanley, T.P.
Wardell, M., see Carrell, R.
Warner, R.L., see Shanley, T.P.

Watson, F., Samples from the Super Highway: NIH, Newsgroups, Pedro's research tools, Visible Human Project (W) 62
Weatherall, D., The molecular basis for phenotypic variability of the common thalassaemias 15
Weiner, D.B., New vaccine strategies (M) 108
Weir, D.M., see Blackwell, C.C.
Welch, C., see Shih, D.M.
Welsh, S., see Jones, R.
Whisstock, J., see Carrell, R.
Winter, R.M., see Reardon, W.
Wood, S., Lambert, R. and Jordan, P.M., Molecular basis of acute intermittent porphyria 232

X

Xu, X., see Heidenreich, O.

Y

Yuen, E.C. and Mobley, W.C., Therapeutic applications of neurotrophic factors in disorders of motor neurons and peripheral nerves 278

Z

Zhou, W., see Andrews, P.A.
Zuckerman, A.J., Infectious Diseases (B) 262

SUBJECT INDEX

Compiled by Carol Featherstone
Abbreviations: (B), The books; (C), The letters; (L), The literature; (M), The meetings; (N), News; (P), Perspectives; (W), The web

A
acid sphingomyelinase-deficient mice
  Niemann-Pick disease (L) 215
acquired immune deficiency syndrome
  see AIDS
acute inflammatory response
  sudden infant death syndrome, SIDS 72
acute intermittent porphyria 232
  metabolic features 232
ADA *see* adenosine deaminase
adenomatosis polyposis coli gene
  DNA methylation (L) 214
  mutant mice (L) 214
adenosine deaminase, ADA
  gene therapy (M) 396
adherens junctions
  tumour progression 84
adrenal chromaffin cell transplants
  Parkinson's disease 181
adult respiratory distress syndrome, ARDS 40
aggrecan
  intervertebral discs 329
aging
  telomeres 378
AIDS (*see also* HIV)
  baboon bone marrow stem cell transplant (N) 349
  gene therapy (M) 396
AIDS pathogenesis
  cytokines (M) 54
AIDS progression
  $CD4^+$ T-cell turnover (N) 2
air pollution
  asthma 149
  constituents 149
airway inflammation 149
allergens
  environmental 292
allergy 149, 292
All in One Internet Search (W) 264
Alzheimer's disease 240
  β-amyloid peptide plaques, BAP (P) 404
  amyloid precursor protein gene, *APP* 240
  apolipoprotein E gene, *APOE* (P) 240, 404
  basal forebrain cholinergic neurons (P) 404
  clinical trials (P) 404
  diagnosis (P) 404
  drugs (P) 404
  energy metabolism 240
  epidemiological studies (P) 404
  genes (N), (L) 210, 261
  genetic heterogeneity 240
  Golgi functions (L) 261
  Leber's hereditary optic neuropathy 240
  microtubules (P) 404
  mitochondrial bottleneck hypothesis 240
  mitochondrial genome mutations 240
  mouse model (N) 1
  paired helical filaments (P) 404
  S182 gene (L) 261
  tau (P) 404
  therapies (P) 404
American Association of Immunology (W) 262
amyloid precursor protein, APP
  Alzheimer's disease, (P) 240, 404
  cellular stress response 240
amyotrophic lateral sclerosis, ALS 195
  neurotrophic factor therapies 278
  superoxide dismutase, SOD (N) 157
anchorage dependence
  tumour progression 84
angiotensin II
  paracrine function 35
  receptors 35
animal rights (P) 220
animals in medical research (P), (L) 220, 308
  alternative techniques to using animals (P) 220, 308
  animal models (P) 220
  attitude surveys (P) 220
  organizations (P) 220, 308
  public perception (P) 220, 308
ankylosing spondylitis 385
antibody delivery of cytotoxic agents 424
  biotoxins 424
  ribonuclease 424
  short-range radioisotopes 424
antibody-directed enzyme prodrug therapy, ADEPT 424
  clinical trial 424
  prodrug–enzyme systems 424
anticoagulation 226
antidepressants
  5-hydroxytryptamine levels (N) 395
antigenic peptides
  synthetic combinatorial libraries 174
antigenic variation
  RNA viruses 248
antigen-specific tolerance (M) 302
antimicrobial compounds
  synthetic combinatorial libraries 174
antisense oligonucleotides 128
  chemical modifications 128
  delivery 128
  inhibition of gene expression 128
  inhibition of HIV 128
  phosphorothioate oligonucleotides 128
  sequence-specific antisense-independent effects 128
  therapies 128
antithrombin 226
  conformational change 226
  crystal structure 226
  kinetic modelling 226
  pentasaccharide-binding site 226
  protease–inhibitor complex formation 226
  thrombin-inhibitory activity 226
antiviral therapy
  RNA viruses 248
anti-vivisectionists (P) 220
Apert syndrome
  FGFR2 gene mutations 432
apoAII gene 364
apoB-containing lipoproteins 364
apoE-deficient mice (L) 56
APOE gene
  Alzheimer's disease, (P) 240, 404
ARDS *see* adult respiratory distress syndrome
arthritis, reactive 385
artificial blood (N) 1
associative memory
  Hermissenda crassicornis (P) 168
  neural networks (P) 168
asthma
  air pollution 149
  airway inflammation 149

atopic 292
epidemiology 149
pathophysiology 149
ataxia–telangiectasia gene
PI 3-kinase similarity (L) 260
rad3 similarity 260
atherogenesis 364
atherosclerosis (L) 56, 364
apoAII gene 364
apoB-containing lipoproteins 364
candidate genes 364
diabetes 364
familial hypercholesterolaemia 90
gene therapy 364
hepatic lipase 364
immune system 364
lipid oxidation 364
Lp(a) 364
obesity 364
quantitative trait loci 364
transgenic mouse models (L) 110, 364
vitamin E transport 364
atherosclerotic lesions 364
atopic diseases 292
aetiology 292
interleukins 292
prevention 292
treatment 292
autoimmune disease
tolerance (M) 302

B

baboon
bone marrow stem cell transplant (N) 349
back pain
intervertebral discs 329
biodegradable polymeric drug delivery systems
applications 134
biomedical resources (W) 301
BioMOO (W) 116
BIOSCI/bionet Electronic Newsgroup Network (W) 62
Biosciences Library (W) 115
biotechnology and the public (B) 306
biotech research, UK (N) 209
bipolar affective disorder
predisposing locus (L) 403
birthweight, associations with
blood coagulation 418
cholesterol metabolism 418
coronary heart disease 418
hypertension 418
insulin resistance 418
non-insulin-dependent diabetes mellitus 418
blood banking
platelets 322
blood–brain barrier
drug delivery (N) 52
site-specific drug delivery systems 134
blood coagulation
birthweight 418
blood substitute 122
bone marrow transplantation (*see also* baboon)
cytomegalovirus infection (L) 400
graft-versus-host disease (L) 353
bovine spongiform encephalopathy, BSE
Creutzfeldt–Jakob disease, CJD (N) 393
brain-derived neurotrophic factor
clinical trials 278
motor neurons 278
BRCA1 gene
public understanding of medical discoveries (P) 359
breast cancer (M) 98, 212
public understanding of medical discoveries (P) 359
bronchiectasis
CFTR gene mutations 336

C

cadherins
tumour progression 84
Caenorhabditis elegans genome sequencing (M) 258
calcineurin
cyclosporin A 287
cancer
cellular senescence 378
gene therapy (L), (M) 304, 396
immunotherapy (M) 396
markers (B) 164
new therapies (M) 212
telomeres 378
vaccines 314
Candida albicans
research funding (N) 300
cannabis
peripheral cannabinoid receptor (N) 158
therapeutic use (N) 158
catenins
tumour progression 84
cationic liposomes
gene therapy 314
$CD4^+$ T-cell turnover
AIDS progression (N) 2
CD34 gene expression (L) 5
cell adhesion
tumour progression 84
cell culture, mammalian (B) 112
cell-free haemoglobin
auto-oxidation 122
chemical and genetic modifications 122
endothelial responses 122
free radicals 122
toxicity 122
cell immortalization
telomerase 378
cellular senescence 378
cancer 378
CFTR gene disruption 140
chemokines
myocarditis (L) 352
chemotherapy
cellular targets 31
drug design 31
peripheral blood progenitor cell transplantation (L) 304
Chief Scientific Advisor, UK government (N) 209
cholesterol metabolism
birthweight 418
chromosome rearrangements
embryonic stem cells (L) 162
homologous recombination (L) 162
junction cloning (M) 212
LIM domains (M) 212
ciliary neurotrophic factor
clinical trials 278
CNS damage
metabolic diseases (N) 52
CNS regeneration
immune privilege (C) 60
macrophages (C) 60
collagens
intervertebral discs 329
combinatorial chemistry 174
combinatorial libraries
divide-couple-recombine process 174
generation and application 174
solid-phase synthesis 174
synthetic 174
comparative genomic hybridization (M) 212
comparative protein modelling 270
complement
cascade 202
glomeruli 202
immune regulator 202
inactivation of retroviral vector particles (L) 163
local functions 202
complement synthesis in tissues
cytokines 202
glomerulus 202
compound libraries 174
drug design 31
computational chemistry
drug design 31
computer modelling
neural networks (P) 168
congenital generalized hypertrichosis locus (L) 215
coronary heart disease
birthweight 418
infant weight gain 418
craniosynostosis
family linkage studies 432
FGFR gene family 432
syndromic forms 432
Creutzfeldt–Jakob disease, CJD 393
crocodile haemoglobin (N) 1
Crohn's disease
aetiology 343
cytokines 343
immune system 343

leprosy, analogies 343
non-perforating 343
perforating 343
Crouzon syndrome
FGFR2 gene mutations 432
cyclophilins
HIV-1 infectivity 287
immunosuppression 287
multiple functions 287
peptidyl-prolyl *cis–trans* isomerase 287
protein folding 287
cyclosporin A
binding proteins 287
calcineurin 287
cytokine expression 287
HIV-1 Gag polyprotein precursor 287
immunosuppression 287
T-cell activation 287
cyclosporins
antiviral activity 287
HIV-1 replication 287
cystic fibrosis
experimental therapies 336
gene therapy (M) 314, 396
cystic fibrosis animal models 336
cystic fibrosis mouse models 140, 336
clinically relevant mutations 140, 314
electrophysiological properties 140
gene therapy 140, 314
lung disease 140
cystic fibrosis transmembrane conductance regulator, CFTR 140, 336
bronchiectasis 336
conserved regions 336
cytokines (B) 7
Crohn's disease 343
expression 287
HIV pathogenesis (M) 54
inflammation 40
oestrogen synthesis 98
Th1/Th2 responses 98
cytomegalovirus infection, CMV
bone marrow transplantation (L) 400
PCR monitoring (L) 400

D

database for cloning genes 373
dehydroepiandrosterone sulphate
breast cancer 98
dendritic cells
donor-derived cells in bone marrow (L) 305
graft acceptance (L) 305
dentatorubral and pallidoluysian atrophy, DRPLA
trinucleotide repeats (L) 163
diabetes
polygenic disease type 1 (N) 2
DiGeorge Syndrome
sequencing (M) 258
diphtheria
herd immunity (N) 52
dipyrromethane cofactor
acute intermittent porphyria 232
discriminant function test 98
discs *see* intervertebral discs
divide-couple-recombine process
combinatorial libraries 174
DNA methylation
tumorigenesis (L) 214
DNA polymerase I
HIV reverse transcriptase (L) 56
DNA vaccines *see* nucleic acid vaccines
dopaminergic neurotrophic factors
Parkinson's disease 181
dopamine-producing cell transplants
Parkinson's disease 181
Down's syndrome
aging 378
screening (M) 398
telomeres 378
DPT immunization
sudden infant death syndrome, SIDS 72
drug delivery (M) 4
localized 134
drug design
computational chemistry 31
structure determination 31
synthetic chemistry 31
drug development (M) 4
biological diversity (M) 4
expressed bacterial genes 373
genome analysis 373
in vivo expression technology 373
target-based screening 373

E

Ebola epidemic (N) 157
electronic publishing
journals and newsletters (W) 400
textbooks (B) 399
ELSI (W) 400
e-mail (W) 10
enterotoxigenic bacteria
sudden infant death syndrome, SIDS 72
enzyme inhibitors
synthetic combinatorial libraries 174
enzyme–prodrug therapy (M), 396, 424
epidermal stem cells (L) 5
epilepsy (B) 354
Epstein–Barr virus, EBV
MHC class I-mediated antigen presentation (L) 214
erythropoietin
renal failure (L) 162
transfected myoblast implants (L) 162
escape mutants
RNA viruses 248
ethical, legal and social implications of genome research, ELSI (W) 400
ethics and bioethics (W) 400
European School of Molecular Medicine (M) 212
ExPASy (W) 356
expressed sequence tags (P) 12
physical map (P) 12

F

familial hypercholesterolaemia 90
atherosclerosis 90
heterozygous 90
LDL receptor 90
familial motor neuron disease 195
candidate genes 195
superoxide dismutase 195
familial thrombotic disease
fetal *see* foetal
fibroblast growth factor receptor gene, *FGFR*
malformation syndromes 432
mutations 432
fibroblast growth factors, FGF
limb bud formation (L) 111
foetal dopamine neuron transplants
Parkinson's disease 181
foetal surgery
ethical questions (P) 310
foetoscopy (P) 310
history (P) 310
open (P) 310
preterm labour (P) 310
foetal tissues
rate of cell division 418
foetal undernutrition 418
foetoscopy (P) 310
folate-sensitive fragile sites
chromosome breaks (L) 305
Food and Drugs Administration, FDA
nicotine (N) 351
reform legislation (N) 300
free radicals
haemoglobin 122

G

gastrointestinal infections (B) 262
GenBank (W) 117
gene analysis (B) 112
gene patenting (P) 12
gene rearrangements
clonal 26
gene targeting (M) 314, 396
gene therapy (M) 396
adeno-associated virus vectors 410
adenosine deaminase, ADA (M) 396
adenovirus vectors 410
AIDS (M) 396
cancer vaccines 314
cationic liposomes 314
clinical trials (M) 396
cystic fibrosis (M) 314, 396
enzyme–prodrug therapy (M) 396
ex vivo 314
gene targeting (M) 314, 396
history 314
homologous recombination 314
immunotherapy for cancer (M) 396

in vivo systems 314
ionizing radiation (L) 304
LDL receptor (M) 396
murine leukaemia virus-based vector, MLV 410
naked DNA 314
non-viral approaches 314
overview 314
positional targeting (M) 396
protocols 410
receptor-mediated gene transfer 314
replication-competent retrovirus (M) 396, 410
retroviral vectors 410
β-thalassaemia 314
transcriptional targeting (M) 396
transkaryotic therapy, TKT 314
vesicular stomatitis virus chimeric vectors, VSV 410
viral vectors (M) 396, 410
Gene Therapy Advisory Committee, GTAC, UK (N) 256
gene therapy regulators (N) 105
genetic epidemiology
obesity 45
genetic immunization (P), (M) 64, 396
human trials (P) 64
genetic literacy (P) 359
genetics (W) 400
genetic screening of populations (N) 394
genetic testing (N) 51
gene vaccines *see* nucleic acid vaccines
genome analysis (M) 258
drug discovery 373
German Human Genome Program (M) 258
Glaxo, Wellcome takeover (N) 3
glial-cell-line-derived neurotrophic factor
clinical trials 278
globin genes
position effects 15
glycoprotein Ib 322
glycoprotein IIb/IIa 322
graft acceptance
dendritic cells (L) 305
graft rejection
Y chromosome genes (N) 394
graft-versus-host disease, GvHD (L)
bone marrow transplantation (L) 353
prophylactic monoclonal antibodies (L) 353
Greig syndrome
GLI3 gene 432

H

Health Sciences Guide (W) 218
haematological oncology (B) 216
haematopoiesis (B) 216
haematopoietic growth factors (B) 216
haematopoietic stem cells
CD34 gene expression (L) 5
transplantation after chemotherapy (L) 304
haem biosynthesis 232
haemoglobin
auto-oxidation 122
cell-free 122
chemical and genetic modifications 122
disorders 15
genetic control 15
structures 15
haemoglobin-based oxygen carriers 122
Haemophilus influenzae
genome sequence (N) 210
type b vaccine (N) 51
haemopoiesis *see* haematopoiesis
Harvard brain atlas (W) 114
HCV
diagnosis of infection 20
genomic organization 20
sequence divergence 20
vaccine development 20
HCV genotypes
classification 20
evolutionary relationships 20
geographical distribution 20
response to interferon 20
health and medicine (W) 400
Helicobacter pylori genome sequence 373
hemoglobin *see* haemoglobin
hemopoiesis *see* haematopoiesis
heparans 226
hepatic lipase 364
hepatitis C 20
hepatitis C virus *see* HCV
herd immunity
diphtheria (N) 51
hereditary non-polyposis colon cancer (P) 12, 373
Hermissenda crassicornis
associative memory (P) 168
herpes simplex virus, HSV
TAP-dependent peptide translocation (L) 214
Hib vaccine (N) 51
HIV-1 Gag polyprotein precursor
cyclosporin A 287
HIV home diagnostic kits (N) 158
HIV-induced disease (M) 54
HIV-1 infectivity
cyclophilin 287
HIV inhibition by antisense oligonucleotides 128
HIV pathogenesis (M) 54
HIV-1 replication
cyclosporins 287
HIV reverse transcriptase
DNA polymerase I (L) 56
HLA-B27
reactive arthritis 385
HLA genes
multiple sclerosis 79
Hodgkin and Reed–Sternberg cells 26
Hodgkin's disease, (B) 26, 216
clonal gene rearrangements 26
monitoring progression 26
pathology and pathogenesis 26
homeopathy (P)
controlled trials (P) 266
history (P) 266
potentization (P) 266
water-imprint theory (P) 266
home pages (W) 10
National Institutes of Health, NIH (W) 62
homologous recombination
chromosome rearrangements (L) 162
gene therapy 314
homology modelling 270
human gene map (N) 53
Human Genetics Commission, UK (N) 256
human genome database (W) 115
Sanger Centre, UK (W) 167
Human Genome Project
drug development 373
Ethical, Legal and Social Implications Program (N), (W) 51, 400
genome analysis (M) 258
German (M) 258
physical map (P), (M) 12, 258
public understanding of medical discovery (P) 359
Venter, J. Craig (P), (N) 12, 210
human immunodeficiency virus *see* HIV
Human Leukocyte Antigens *see* HLA
Huntington's disease
locus sequencing (M) 258
trinucleotide repeats (L) 163
Hutchison–Gilford progeria
aging 378
telomeres 378
H-Y antigens (N) 394
hyperlipoproteinemia, type III (L) 56
hypertension
birthweight 418
intrauterine programming 418
placental weight 418

I

Image Library of Biological Macromolecules (W) 218
immune deviation
atopic diseases 292
immune privilege
CNS (C) 60
immunoglobulin gene rearrangements
Hodgkin's disease 26
immunosuppression 287
immunosuppressive drugs
transplantation (M) 302
infectious diseases (B) 262
aetiology (M) 160
Africa (M) 160
Pasteur, Louis (M) 160
pathogenesis (M) 160
inflammation
adhesion molecules 40
cytokines 40
neutrophil recruitment 40
inherited diseases (B) 399
Institute Pasteur, The (W) 356

insulin-dependent diabetes mellitus (N) 2
insulin gene (N) 2
insulin-like growth factor 1
  amyotrophic lateral sclerosis, ALS 278
  clinical trials 278
insulin resistance
  birthweight 418
integrins
  tumour progression 84
β_1-integrin
  epidermal stem cells (L) 5
β_2-integrins
  inflammation 40
interferons, IFN
  antiviral effects (M) 54
interleukin 1, IL-1
  inflammation 40
interleukin-1β gene polymorphism
  psoriasis (N) 256
interleukin 7, IL-7
  human intestinal epithelial cells (L) 260
interleukin 7 receptors
  lamina propria lymphocytes (L) 260
interleukins
  atopic diseases 292
International Society of Nephrology and Renal Pathology (W) 264
Internet (W)
  service providers (W) 10
intervertebral discs
  aetiology of degeneration 329
  aggrecan 329
  back pain 329
  collagens 329
  degeneration 329
  development 329
  pathological changes 329
  structure 329
intrauterine programming of adult disease 418
ionizing radiation
  mRNA sequence activation 304

J

Jacobsen syndrome
  folate-sensitive fragile sites (L) 305
Jak-3 gene mutations
  lymphoid development (L) 353
  severe combined immune deficiency (L) 353
jejuno-ileal bypass surgery
  reactive arthritis 385

L

lactoferrin
  sequence-specific DNA binding (L) 57
LDL receptor
  cell biology 90
  familial hypercholesterolaemia 90
  function 90
  mutations 90
Leber's hereditary optic neuropathy
  Alzheimer's disease 240
legal affairs (W) 400
Leishmania
  lipophosphoglycan biosynthesis (L) 402
leprosy
  analogies to Crohn's disease 343
leukaemia
  new treatments (N) 107
leukocyte–endothelial cell interactions
  inflammation 40
limb bud formation (L) 111
lipophosphoglycan biosynthesis, lpg
  Leishmania (L) 402
local drug delivery
  biodegradable polymeric delivery systems 134
low-density-lipoprotein receptor *see* LDL receptor
Lp(a) 364
Lycos (W) 114
lysosomal storage diseases
  neural progenitor cell implants (L) 111

M

macrophage inflammatory protein 1α, MIP-1α
  inflammatory-cell recruitment (L) 352
  knock-out mice (L) 352
  myocarditis (L) 352
macrophages
  CNS regeneration (C) 60
magnetic resonance elastography, MRE (N) 395
major histocompatibility complex *see* MHC
malaria (W) 356
Malaria Weekly on-line (W) 356
malformation syndromes
  fibroblast growth factor receptor gene mutations 432
management training (B) 306
Medline Subset in Molecular Genetics (W) 262
metastasis 84
MHC
  rejection of donor tissue (N) 394
MHC class I
  viral persistence (L) 214
microbial genome sequencing
  drug development 373
microbial pathogenicity (B) 262
microorganisms
  sudden infant death syndrome, SIDS 72
minor histocompatibility 394
mitochondrial bottleneck hypothesis
  Alzheimer's disease 240
molecular biology (B) 112
molecular combing (M) 258
molecular genetics primer
  Department of Energy, USA (W) 166
molecular oncology (M) 212
monoclonal antibodies (B) 58
  diagnostics (B) 58
  genetic engineering (B) 58
  prophylactic (L) 353
monogenic diseases 15
motor neuron disease, MND (B) 195, 354
  aetiology 195
  familial 195
  neurotrophic factor therapies 278
  pathogenesis 195
  sporadic 195
  subtypes 195
  superoxide dismutase, SOD (N) 157, 195
mouse genome sequencing
  drug development 373
mouse models
  atherosclerosis 364
  Niemann-Pick disease (L) 215
  obesity 45
  renal failure (L) 162
mucopolysaccharidosis VII
  neural progenitor cell implants (L) 111
mucosal immune response
  interleukin 7, IL-7 (L) 260
multidrug-resistant tuberculosis (M) 160
Multimedia Medical Reference Library (W) 218
multiple sclerosis
  HLA genes 79
  immune response 79
  myelin basic protein epitopes, MBP 79
  pathogenesis 79
  T-cell responses 79
  tolerization 79
Mycobacterium leprae 343
Mycobacterium tuberculosis (M), (N) 53, 160
Mycoplasma genitalium
  genome sequence (N) 210
myelin basic protein epitopes, MBP
  multiple sclerosis 79

N

naked DNA technology (P) 64
National Cancer Institute, NCI, USA (W) 218
National Center for Biotechnology Information, NCBI, USA (W) 262
National Institutes of Health
  Candida albicans research funding (N) 300
  home page (W) 62
  research grants (N) 106, 211
nerve growth factor, NGF
  clinical trials 278
neural networks (P)
  hundred-step rule (P) 168
  parallel distributed processing (P) 168
  synaptic strength parameters (P) 168

neural progenitor cell implants (L), (N) 111, 350
neurodegenerative diseases
  motor neuron disease 195, 278
  trinucleotide repeats (L) 163
neurological disorders, (B) 278, 354
neuronal apoptosis-inhibitory protein gene (L) 5
neuroplasticity
  gangliosides (N) 158
neurosciences page (W) 218
neurotrophic factors
  clinical trials 278
  therapeutics (N) 159, 278
neurotrophin 3
  clinical trials 278
  sensory neuron survival 278
neurotrophins
  clinical trials 278
neutrophil recruitment
  inflammation 40
nicotine
  Food and Drug Administration, FDA, USA (N) 351
Niemann-Pick disease
  mouse model (L) 215
nitric oxide, NO (M)
  blood pressure homeostasis (L) 110
  pathogenesis (M) 358
  septic shock (L) 110
nitric oxide synthase, NOS
  inflammation 40
  knock-out mice (M) 358
nitrogen dioxide
  asthma 149
non-Hodgkin's lymphoma (B) 216
nucleic acid vaccines (P), (M) 64, 108
  delivery systems (M) 108
  ethical considerations (M) 108
  viral pathogens (M) 108
nutraceutical research
  Japan (P) 118
nutraceuticals (P) 118
  European Union legislation (P) 118
Nutritional Labelling and Education Act (P) 118

O

obese gene cloning 45, 373
obesity
  DNA sequence variation 45
  experimental overfeeding 45
  genetic basis 45
  genetic epidemiology 45
  quantitative trait locus mapping 45
  sib-pair linkage analysis 45
  single-gene mouse models 45
  transgenic mouse models 45
oestrogens
  breast cancer 98
  postmenopausal women 98
oestrogen synthesis 98
  cytokine regulation 98
OMNI project (W) 301
oncogenes (B) 164
oncology (M), (B) 212, 216
Online Mendelian Inheritance in Man, OMIM (W) 15
open foetal surgery (P) 310
oral tolerance to antigens 292
organic chemical libraries 174
organizing medical networked information *see* OMNI
Orphan Drug Act, USA 118
osteomyelitis
  site-specific drug delivery systems 134
ozone
  asthma 149

P

paired helical filaments
  Alzheimer's disease (P) 404
parainfluenza virus type 3
  allogenic cytotoxicity (L) 214
  T-cell activation (L) 214
parasitic disease control (N) 159
Parkinson's disease
  adrenal chromaffin cell transplants 181
  dopamine-producing cell transplants 181
  dopaminergic neurotrophic factors 181
  foetal dopamine neuron transplants 181
  future research agenda (N) 350
  genetic manipulations of the brain 181
  genetically modified cell transplants 181
  rat model 181
  therapeutic strategies 181
Pasteur, Louis (M) 160
PCR
  monitoring cytomegalovirus infection (L) 400
  single cell 26
Pedro's research tools (W) 63
peptidoglycan polysaccharide 385
peptidomimetic chemical libraries 174
peptidyl-prolyl *cis–trans* isomerase cyclophilin 287
peripheral blood progenitor cells
  ex vivo expansion (L) 304
  transplantation (L) 304
peripheral cannabinoid receptor (N) 158
peripheral nerve regeneration (L) 5
peripheral nervous system diseases
  neurotrophic factor therapies 278
Persian Gulf War syndrome (N) 299
Pfeiffer syndrome
  FGFR1 and *FGFR2* gene mutations 432
phage display system
  monoclonal antibodies (B) 58
pharmaceutical research
  lead compounds 31
philosophy (W) 400
phospholipase A_2, secreted group II
  inflammation (C) 9
phosphorothioate oligonucleotides 128
physiologically functional foods 118
  European Union legislation 118
Plasmodium see malaria
platelet
  blood banking 322
  glycoprotein Ib 322
  glycoprotein IIb/IIa 322
  lyophilization 322
  morphology 322
  storage 322
platelet concentrates
  shelf life 322
platelet-storage lesion 322
poison gas attack (N) 52
polymerase chain reaction *see* PCR
porphobilinogen deaminase
  acute intermittent porphyria 232
  dipyrromethane cofactor 232
  gene mutations 232
  structure and mechanism 232
porphyria 232
positional targeting
  gene therapy (M) 396
position effects
  globin genes 15
potentization
  homeopathy (P) 266
predictive medicine (P) 359
preproendothelin-1 promoter 110
preterm labour
  open foetal surgery (P) 310
primary lateral sclerosis 195
prion disease (N) 393
prodrug–enzyme systems 424
progressive muscular atrophy 195
prostaglandin E2, PGE2
  Th1 response (C) 61
proteasome inhibitors (N) 256
protein folds
  fold classes 188
  fold recognition 188
protein kinase DAI
  antisense oligonucleotides 128
protein structure prediction 188
  algorithm (N) 257
  comparative protein modelling 270
  fold classes 188
  fold recognition 188
psoriasis
  IL-1β gene polymorphism (N) 256
psychosocial factors
  ill-health (N) 3
public understanding of medical discovery
  books (P) 359
  BRCA1 gene (P) 359
  breast cancer (P) 359
  genetic literacy (P) 359
  Human Genome Programme (P) 359
  predictive medicine (P) 359
pyrogenic toxins
  sudden infant death syndrome, SIDS 72

Q
quantitative trait locus mapping, QTL
atherosclerosis 364
obesity 45
quasispecies
RNA viruses 248

R
radiation hybrid mapping (M) 258
rat model
HLA-B27 385
Parkinson's disease 181
reactive arthritis
RB gene *see* retinoblastoma gene
reactive arthritis 385
aetiology 385
ankylosing spondylitis 385
enteric bacteria overgrowth 385
genetic susceptibility 385
HLA-B27 385
intestinal inflammation 385
jejuno-ileal bypass surgery 385
peptidoglycan polysaccharide 385
transgenic rat model 385
receptor ligands
synthetic combinatorial libraries 174
receptor-mediated gene transfer 314
Recombinant DNA Advisory Committee, RAC, USA
germline gene therapy (N) 105
reference resources (W) 400
renal failure
erythropoietin (L) 162
mouse model (L) 162
transfected myoblast implants (L) 162
renal injury
complement 202
renin–angiotensin system
sodium and potassium homeostasis 35
tissues 35
replication-competent retrovirus
gene therapy (M) 396, 410
representational difference analysis (L) 56
respiratory viruses
sudden infant death syndrome, SIDS 72
retinoblastoma gene, *RB*
smooth muscle cell proliferation (L) 57
retroviral vector particles
complement inactivation (L) 163
monoclonal antibodies (L) 163
retroviral vectors
gene therapy 410
murine leukaemia virus-based vector, MLV 410
RNA isolation and analysis (B) 112
RNA viruses
antigenic variation 248
antiviral therapy 248
escape mutants 248
evolution 248
human diseases 248
immunodominant epitopes 248
live-attenuated virus vaccines 248
peptide vaccines 248
quasispecies 248
vaccine design 248
Royal Society, UK
new foreign members (N) 2

S
Sandoz Prizes for Immunology (N) 255
Sanger Centre, UK (W) 167
sarin (N) 52
Schiff-base-forming drugs
T-cell responses (L) 352
Schwann cell
peripheral nerve regeneration (L) 5
SCID *see* severe combined immune deficiency
science and society (W) 400
science education (W) 400
scientific integrity (B) 306
selectins
inflammation 40
serpins 226
service provider (W) 10
severe combined immune deficiency, SCID
Jak-3 gene mutations (L) 353
lymphoid development (L) 353
sexually transmitted diseases (M) 160
SIDS *see* sudden infant death syndrome
single-cell PCR 26
site-specific drug delivery systems 134
applications 134
SMCX gene (N) 394
SMCY gene
graft rejection (N) 394
smooth muscle cell proliferation
retinoblastoma gene (L) 57
social issues (W) 400
solid-phase synthesis 174
spinal cord injury
gangliosides (N) 158
spinal muscular atrophy genes, SMA (L) 5
spinocerebellar ataxia type I
trinucleotide repeats (L) 163
Staphylococcus aureus
vancomycin resistance (N) 105
stem cell transplants (*see also* baboon) (N) 107
structure determination
drug design 31
sudden infant death syndrome, SIDS
accute inflammatory response 72
DPT immunization 72
enterotoxigenic bacteria 72
epidemiology 72
inflammatory responses 72
microorganisms 72
pyrogenic toxins 72
respiratory viruses 72
synergistic factors 72
sulphur dioxide
asthma 149
superoxide dismutase, SOD
gain-of-function mutation 195
motor neuron disease (N) 157, 195
survival motor neuron gene (L) 5
synthetic chemistry
drug design 31
synthetic combinatorial libraries
antigenic peptides 174
antimicrobial compounds 174
enzyme inhibitors 174
positional scanning 174
receptor ligands 174
screening 174
synthetic peptide libraries 174

T
TAP-dependent peptide translocation (L) 214
tau
Alzheimer's disease (P) 404
T-cell activation
cyclosporins 287
Schiff-base-forming drugs (L) 352
T-cell acute lymphoblastic leukaemia
TAL-1 gene (L) 352
T-cell antigen receptor
autoimmunity (L) 403
T-cell antigen receptor gene rearrangements
Hodgkin's disease 26
telomerase
cell immortalization 378
telomeres
aging 378
thalassaemias
gene-dosage effects 15
gene therapy 314
genotype/phenotype relationships 15
transcription factor genes 15
thalidomide
mutagen (N) 210
thanathophoric dysplasia
FGFR3 gene mutations 432
Th cells
atopic diseases 292
IgE responses 292
Th1/Th2 responses
breast cancer 98
prostaglandin E2, PGE2 (C) 61
T-helper cells *see* Th cells
The Institute for Genomic Research (TIGR), USA (P) 12
thrombin 226
thrombosis 226
tissue repair (N) 351
tobacco industry
nicotine (N) 351
Tokyo underground
poison gas attack (N) 52
tolerance
antigen specific (M) 302
autoimmune disease (M) 302
mechanisms (M) 302

multiple sclerosis 79
transplantation (M) 302
tolerization
multiple sclerosis 79
transcriptional maps (M) 258
transcriptional targeting
gene therapy (M) 396
transgenic mice
drug development 373
transkaryotic therapy, TKT 314
transcription factor genes 15
transgenic mouse models
atherosclerosis (L) 110
transplantation
antigen-specific tolerance (M) 302
immunosuppressive drugs (M) 302
rejection of donor tissue from males (N) 394
tolerance induction (M) 302
trinucleotide repeats
CBL2 gene (L) 304
folate-sensitive fragile sites (L) 304
neurodegenerative diseases (L) 163
Tropical Disease Research Units (N) 159
tuberculosis vaccine (N) 53
tumor *see* tumour
tumorigenesis
DNA methylation (L) 214
tumour necrosis factor α, TNF-α
inflammation 40
tumour probes (L) 56
tumour progression 84
cell adhesion 84
tumour suppressor genes (B) 164

U
ulcerative colitis 336

V
vaccines
live-attenuated virus 248
nucleic acid (P), (M) 64, 108
peptide 248
RNA viruses 248
vascular disorders
site-specific drug delivery systems 134
Venter, J. Craig (P), (N) 12, 210
vesicular stomatitis virus chimeric vectors, VSV 410
viral persistence
immune surveillance (L) 214
viral vectors
adeno-associated virus vectors, AAV 410
adenovirus vectors 410
gene therapy (M) 396
murine leukaemia virus-based vector, MLV 410
vesicular stomatitis virus chimeric vectors, VSV 410
Virtual Library (W) 115
Visible Human Project (W) 63
vitamin E transport
apoB-knockout mice 364

W
water-imprint theory
homeopathy (P) 266
WebCrawler (W) 114
Wellcome takeover (N) 3
werewolf locus 215
WHO Malaria Database (W) 356
WHOSIS (W) 356
World Health Organization, WHO (W) 167
malaria database (W) 356
World Wide Web (W) 10
biomedical resources (W) 301
OMNI project (W) 301
World Wide Web Worm (W) 166